Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and/or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Patients With Stable Ischemic Heart Disease and Preserved Left Ventricular Systolic Function
Overall Summary of the Evidence-Based Harms of Adding an ACEI or an ARB to Standard Medical Therapy for Stable Ischemic Heart Disease With Preserved Left Ventricular Systolic Function
This slide provides an overall summary of the evidence-based harms of adding an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II-receptor blocker (ARB) to standard medical therapy for patients with stable ischemic heart disease and preserved left ventricular systolic function, as compared to standard medical therapy alone or with a placebo. The strength or level of evidence associated with each outcome, as assessed in the Comparative Effectiveness Review, is also indicated.
Although many of the trials included in the CER analyses reported harms data, the reporting of adverse events was not consistent across the trials. Additionally, several trials included a prerandomization run-in period, during which subjects who could not tolerate the trial drug were excluded. Such exclusion may limit the applicability of the harms data for the overall population with stable ischemic heart disease.
- Coleman CI, Baker WL, Kluger J, et al. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II-Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease. Comparative Effectiveness Review No. 18. (Prepared by the University of Connecticut/Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I.) Rockville, MD: Agency for Healthcare Research and Quality; October 2009.
Your slide tray is being processed.